Biosciences
Activities led by Venture Partners at ñ, the university’s commercialization arm, generated an economic impact of $8 billion nationally and $5.2 billion in the state of Colorado over the last five years.
Breathalyzer based on frequency comb spectroscopy quantum tech shows promise as a non-invasive diagnostic test for an array of diseases.
When pregnant moms breathe dirty air, it may adversely impact their baby’s brain, ñ research suggests.
ñ’s International Genetically Engineered Machine team has developed a “magic soybean” that can churn out scarce pharmaceutical compounds while going easy on the environment.
Researchers building a budding life sciences startup leverage venture development programming to achieve a major funding milestone.
Cheaper, faster test trades uncomfortable nose swab for spit-in-a-tube simplicity in effort to detect virus before it spreads
With antibiotic-resistant “superbugs” infecting 2 million people per year, and a dearth of new medications in the pipeline to treat them, ñ researchers are taking a novel approach to addressing the looming public health crisis.
New shelf-stable vaccines could bolster lifesaving immunization deliveries worldwide.
Mounting evidence shows healthy resident bacteria can play a pivotal role in supporting physical health.